[go: up one dir, main page]

DE69232034D1 - Aerosolzusammensetzungen für Arzneimittelsuspensionen - Google Patents

Aerosolzusammensetzungen für Arzneimittelsuspensionen

Info

Publication number
DE69232034D1
DE69232034D1 DE69232034T DE69232034T DE69232034D1 DE 69232034 D1 DE69232034 D1 DE 69232034D1 DE 69232034 T DE69232034 T DE 69232034T DE 69232034 T DE69232034 T DE 69232034T DE 69232034 D1 DE69232034 D1 DE 69232034D1
Authority
DE
Germany
Prior art keywords
aerosol compositions
drug suspensions
aerosol formulation
suspensions
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69232034T
Other languages
English (en)
Other versions
DE69232034T2 (de
Inventor
Robert K Schultz
David W Schultz
Martin J Oliver
Robert A Moris
Philip A Jinks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232034(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of DE69232034D1 publication Critical patent/DE69232034D1/de
Publication of DE69232034T2 publication Critical patent/DE69232034T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
DE69232034T 1991-12-18 1992-12-11 Aerosolzusammensetzungen für Arzneimittelsuspensionen Revoked DE69232034T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81040191A 1991-12-18 1991-12-18
US80979191A 1991-12-18 1991-12-18
US87803992A 1992-05-04 1992-05-04

Publications (2)

Publication Number Publication Date
DE69232034D1 true DE69232034D1 (de) 2001-10-04
DE69232034T2 DE69232034T2 (de) 2002-06-06

Family

ID=27420051

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69232034T Revoked DE69232034T2 (de) 1991-12-18 1992-12-11 Aerosolzusammensetzungen für Arzneimittelsuspensionen
DE69233319T Expired - Lifetime DE69233319T2 (de) 1991-12-18 1992-12-11 Aerosolzusammensetzungen für Arzneimittelsuspensionen
DE69218455T Revoked DE69218455T2 (de) 1991-12-18 1992-12-11 Aerosolzusammensetzungen für arzneimittelsuspensionen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69233319T Expired - Lifetime DE69233319T2 (de) 1991-12-18 1992-12-11 Aerosolzusammensetzungen für Arzneimittelsuspensionen
DE69218455T Revoked DE69218455T2 (de) 1991-12-18 1992-12-11 Aerosolzusammensetzungen für arzneimittelsuspensionen

Country Status (13)

Country Link
US (2) US6743413B1 (de)
EP (3) EP0617610B1 (de)
JP (2) JP3908269B2 (de)
AT (3) ATE150296T1 (de)
AU (2) AU675633B2 (de)
CA (2) CA2320129C (de)
DE (3) DE69232034T2 (de)
DK (3) DK0717987T3 (de)
ES (3) ES2159678T3 (de)
GR (2) GR3022874T3 (de)
NZ (1) NZ246421A (de)
PT (2) PT1086688E (de)
WO (1) WO1993011747A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233659T2 (de) 1991-06-10 2007-09-13 Schering Corp. Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
DK0616525T3 (da) * 1991-12-12 1996-01-08 Glaxo Group Ltd Medikamenter
AU663905B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
DE69232034T2 (de) * 1991-12-18 2002-06-06 Minnesota Mining And Mfg. Co., Saint Paul Aerosolzusammensetzungen für Arzneimittelsuspensionen
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
WO1995024892A1 (en) * 1994-03-14 1995-09-21 Abbott Laboratories Aerosol drug formulations containing vitamin e
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
CA2213638C (en) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
GB9620187D0 (en) † 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU750567B2 (en) * 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
IL142494A0 (en) * 1998-10-17 2002-03-10 Boehringer Ingelheim Pharma Storable active substance concentrate with formoterol
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6739333B1 (en) 1999-05-26 2004-05-25 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
DE19924098A1 (de) * 1999-05-26 2000-12-07 Boehringer Ingelheim Pharma Edelstahlkanister für treibgasbetriebene Dosieraerosole
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
GB9924808D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Medicament dispenser
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1273292B1 (de) 2001-07-02 2004-05-26 CHIESI FARMACEUTICI S.p.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
PT1455755E (pt) 2001-11-20 2013-06-18 Civitas Therapeutics Inc Composições particuladas melhoradas para distribuição pulmonar
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
DK1572622T3 (da) 2002-12-10 2006-08-28 Sepracor Inc Anvendelse af levalbuterol-L-tartrat ved fremstilling af en doseringsinhalator
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
WO2004110460A1 (en) * 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
WO2005032521A2 (en) * 2003-10-02 2005-04-14 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
EP1949891A1 (de) 2004-10-12 2008-07-30 Generics (UK) Limited Verfahren zur Herstellung von Suspensionsaerosolformulierungen, wobei die Partikel durch Fällung im Innenkanister gebildet werden
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20080112886A1 (en) * 2006-09-08 2008-05-15 The Regents Of The University Of California Engineering shape of polymeric micro- and nanoparticles
US7754096B2 (en) * 2007-02-01 2010-07-13 E.I. Du Pont De Nemours And Company Liquefied-gas aerosol dusting composition containing denatonium benzoate
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
CN102014779B (zh) 2008-05-09 2014-10-22 赫莱拉公司 用于治疗支气管树的系统、组件和方法
WO2010091198A1 (en) 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
PL2453894T3 (pl) 2009-07-15 2016-04-29 Theravance Biopharma R&D Ip Llc Postać krystaliczna wolnej zasady związku bifenylowego
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
CA2779135C (en) 2009-10-27 2018-09-04 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
CA2780608C (en) 2009-11-11 2019-02-26 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
JP2013512193A (ja) 2009-11-24 2013-04-11 ギリアード サイエンシーズ， インコーポレイテッド 慢性閉塞性肺疾患の処置のための吸入型ホスホマイシン／トブラマイシン
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2542082B8 (de) 2010-03-03 2020-06-17 Neonc Technologies Inc. PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT (S)-Perillylalkohol
KR101924162B1 (ko) 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
JP5807058B2 (ja) 2010-05-10 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 二機能キノリン誘導体
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
EP2898883B1 (de) 2010-08-27 2016-11-23 Neonc Technologies Inc. Pharmazeutische Zusammensetzungen mit Perillylalcohol-Carbamaten
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
DK2651864T3 (en) 2010-12-17 2016-09-05 Neonc Tech Inc Methods and devices for use of isoperillylalkohol
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EP3366680B1 (de) 2012-05-29 2020-05-13 Parion Sciences, Inc. Dendrimerähnliche aminoamide mit natriumkanalblockeraktivität zur behandlung von xerophthalmie und anderen schleimhauterkrankungen
US9012490B2 (en) * 2012-08-17 2015-04-21 Howard University Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
HK1216250A1 (zh) 2012-12-21 2016-10-28 Map Pharmaceuticals, Inc. 8'-羟基-二氢麦角胺化合物及组合物
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
PT2968312T (pt) 2013-03-15 2018-04-19 Verona Pharma Plc Combinação de fármacos
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
US9522918B2 (en) 2015-02-12 2016-12-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
US10858305B2 (en) 2016-11-30 2020-12-08 Neonc Technologies, Inc. Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (de) 1956-03-21 1900-01-01
US2885427A (en) 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (de) 1957-01-31 1957-04-11
BE629985A (de) 1962-11-29
US3320125A (en) 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3809294A (en) 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US3895111A (en) 1973-06-27 1975-07-15 American Cyanamid Co Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IL51314A (en) 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
JPS5325284A (en) 1976-08-19 1978-03-08 Daikin Ind Ltd Aerosol composition
US4129603A (en) 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
ATE3774T1 (de) 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
US4311863A (en) 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
JPS60224638A (ja) 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US4767612A (en) * 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
US4851595A (en) 1987-07-07 1989-07-25 E. I. Du Pont De Nemours And Company Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5206268A (en) 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828544D0 (en) 1988-12-07 1989-01-11 Ici Plc Chemical process
DE3905726A1 (de) 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
US4945119A (en) 1989-05-10 1990-07-31 The Dow Chemical Company Foaming system for rigid urethane and isocyanurate foams
US4940171A (en) 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
AU633584B2 (en) 1989-06-15 1993-02-04 Tokyo Tanabe Company Limited Aerosols of pyrido(1,2-a)pyrimidine compounds
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5254755A (en) 1990-12-04 1993-10-19 Allied-Signal Inc. Partially fluorinated alkanols having a tertiary structure
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US5182040A (en) 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
DE69233659T2 (de) 1991-06-10 2007-09-13 Schering Corp. Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
ATE134509T1 (de) 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
WO1992022286A1 (en) * 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DK0616525T3 (da) 1991-12-12 1996-01-08 Glaxo Group Ltd Medikamenter
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU663905B2 (en) 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5674471A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
DE69232034T2 (de) * 1991-12-18 2002-06-06 Minnesota Mining And Mfg. Co., Saint Paul Aerosolzusammensetzungen für Arzneimittelsuspensionen
GB9200148D0 (en) * 1992-01-06 1992-02-26 Minnesota Mining & Mfg Aerosol valves
US5202110A (en) 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US5314682A (en) 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6013245A (en) 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations

Also Published As

Publication number Publication date
DE69232034T2 (de) 2002-06-06
EP0617610A1 (de) 1994-10-05
EP1086688A1 (de) 2001-03-28
GR3022874T3 (en) 1997-06-30
US6743413B1 (en) 2004-06-01
JP3908269B2 (ja) 2007-04-25
GR3036467T3 (en) 2001-11-30
DK0717987T3 (da) 2001-11-12
ATE204743T1 (de) 2001-09-15
EP0617610B1 (de) 1997-03-19
DE69218455T2 (de) 1997-10-23
EP0717987B1 (de) 2001-08-29
JPH07502275A (ja) 1995-03-09
JP2004143183A (ja) 2004-05-20
EP0717987A3 (de) 1996-07-03
ES2216800T3 (es) 2004-11-01
ATE260641T1 (de) 2004-03-15
AU3272893A (en) 1993-07-19
EP0717987A2 (de) 1996-06-26
CA2320129C (en) 2003-02-11
DK0617610T3 (da) 1997-10-06
ATE150296T1 (de) 1997-04-15
DE69218455D1 (de) 1997-04-24
DK1086688T3 (da) 2004-08-16
EP1086688B1 (de) 2004-03-03
ES2099415T3 (es) 1997-05-16
AU1234297A (en) 1997-03-20
PT1086688E (pt) 2004-06-30
CA2126244A1 (en) 1993-06-24
NZ246421A (en) 1996-05-28
AU675633B2 (en) 1997-02-13
DE69233319D1 (de) 2004-04-08
US20040197273A1 (en) 2004-10-07
PT717987E (pt) 2001-12-28
CA2320129A1 (en) 1993-06-24
WO1993011747A1 (en) 1993-06-24
AU709052B2 (en) 1999-08-19
DE69233319T2 (de) 2005-02-17
AU709052C (en) 2002-04-11
CA2126244C (en) 2000-09-26
ES2159678T3 (es) 2001-10-16

Similar Documents

Publication Publication Date Title
DE69232034D1 (de) Aerosolzusammensetzungen für Arzneimittelsuspensionen
DK0553298T3 (da) Aerosolformulering omfattende beclomethason-17,21-dipropionat
EP1277467A3 (de) Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
ATE246497T1 (de) Fluorchlorkohlenwasserstoffreie aerosolformulierungen
NO980858D0 (no) Farmasöytiske preparater og anordninger for administrering derav
DK0579996T3 (da) 5,10-Methylentetrahydrofolsyrecyclodextrin-inklusionsforbindelser
HU9500401D0 (en) 3-and 5-substituted 1,2,3,4-oxatriazole-5-iminined derivatives, a process for the preparation thereof, use of said compounos for the preparation of medicaments and pharmaceutical compositions containing said compounds
NO950484D0 (no) 3- og 5-substituerte 1,2,3,4-oksatriazol-5-iminforbindelser, fremgangsmåte for fremstilling derav, farmasöytisk preparat inneholdende forbindelsene samt anvendelse av slike for fremstilling av medikamenter

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation